Abstract:A female infant, aged 43 days, had shortness of breath, cyanosis, groan, and dyspnea since birth. Physical examination showed cyanosis of lips and three-concave sign, and multiple lung imaging examinations showed diffuse ground-glass opacities in both lungs. The girl was given anti-infective therapy and continuous mechanical ventilation but there were no significant improvements in symptoms. Gene testing confirmed a compound heterozygous mutation, c.1890C > A(p.Tyr630Ter)+c.3208G > A(p.Ala1070Thr), in the ABCA3 gene, with the former from her father and the latter from her mother. Pathological examination of the lungs indicated pulmonary interstitial disease. The girl was diagnosed with infantile diffuse pulmonary interstitial disease caused by mutations in the ABCA3 gene. When full-term neonates experience shortness of breath and dyspnea after birth, pulmonary imaging suggests diffuse ground-glass changes, and conventional treatment is not effective (ventilator-dependent), congenital pulmonary surfactant metabolism defects needs to be considered. Gene testing, which can provide a basis for early intervention, prognostic evaluation, and genetic counseling, should be performed as early as possible.
Lee EY, Cleveland RH, Langston C. Interstitial lung disease in infants and children:new classification system with emphasis on clinical, imaging, and pathological correlation[M]//Cleveland R. Imaging in Pediatric Pulmonology. Boston, MA:Springer, 2012:99-154.
[3]
Kurland G, Deterding RR, Hagood JS, et al. An official American Thoracic Society clinical practice guideline:classification, evaluation, and management of childhood interstitial lung disease in infancy[J]. Am J Respir Crit Care Med, 2013, 188(3):376-394.
[4]
Richards S, Aziz N, Bale S, et al. Standards and guidelines for the interpretation of sequence variants:a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology[J]. Genet Med, 2015, 17(5):405-424.
[5]
Wambach JA, Casey AM, Fishman MP, et al. Genotype-phenotype correlations for infants and children with ABCA3 deficiency[J]. Am J Respir Crit Care Med, 2014, 189(12):1538-1543.
[6]
Weichert N, Kaltenborn E, Hector A, et al. Some ABCA3 mutations elevate ER stress and initiate apoptosis of lung epithelial cells[J]. Respir Res, 2011, 12(1):4.
[7]
Shulenin S, Nogee LM, Annilo T, et al. ABCA3 gene mutations in newborns with fatal surfactant deficiency[J]. N Engl J Med, 2004, 350(13):1296-1303.
[8]
Beers MF, Mulugeta S. The biology of the ABCA3 lipid transporter in lung health and disease[J]. Cell Tissue Res, 2017, 367(3):481-493.
Doan ML, Guillerman RP, Dishop MK, et al. Clinical, radiological and pathological features of ABCA3 mutations in children[J]. Thorax, 2008, 63(4):366-373.
[11]
Parappil H, Al Baridi A, ur Rahman S, et al. Respiratory distress syndrome due to a novel homozygous ABCA3 mutation in a term neonate[J]. BMJ Case Rep, 2011, 2011:bcr1020103427.
[12]
Kröner C, Wittmann T, Reu S, et al. Lung disease caused by ABCA3 mutations[J]. Thorax, 2017, 72(3):213-220.
[13]
Hallik M, Annilo T, Ilmoja ML. Different course of lung disease in two siblings with novel ABCA3 mutations[J]. Eur J Pediatr, 2014, 173(12):1553-1556.
[14]
Ciantelli M, Ghirri P, Presi S, et al. Fatal respiratory failure in a full-term newborn with two ABCA3 gene mutations:a case report[J]. J Perinatol, 2011, 31(1):70-72.
[15]
Uchida DA, Wert SE, Nogee LM, et al. Pulmonary nodules in a newborn with ATP-binding cassette transporter A3(ABCA3) mutations[J]. Pediatrics, 2011, 127(5):e1347-e1351.
[16]
Agrawal A, Hamvas A, Cole FS, et al. An intronic ABCA3 mutation that is responsible for respiratory disease[J]. Pediatr Res, 2012, 71(6):633-637.
[17]
Gonçalves JP, Pinheiro L, Costa M, et al. Novel ABCA3 mutations as a cause of respiratory distress in a term newborn[J]. Gene, 2014, 534(2):417-420.
[18]
Mitsiakos G, Tsakalidis C, Karagianni P, et al. A new ABCA3 gene mutation c.3445G>A (p.Asp1149Asn) as a causative agent of newborn lethal respiratory distress syndrome[J]. Medicina (Kaunas), 2019, 55(7):389.
[19]
Tan JK, Murray C, Schultz A. ABCA3 lung disease in an ex 27 week preterm infant responsive to systemic glucocorticosteroids[J]. Pediatr Pulmonol, 2016, 51(1):E1-E3.